HealthQuill Clinical trials
Bayer AG, a German pharmaceutical major, will seek regulatory approval for its menopausal drug after the final trials proved to reduce hot flashes.
Drugs Health Pharma

Bayer’s menopausal drug lowers hot flashes, to seek regulatory nod

HQ Team March 19, 2024: Bayer AG, a German pharmaceutical major, will seek regulatory approval for its menopausal drug after the final trials.

Read More
Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded positive results and improved overall survival rates.
Drugs Health Pharma

Pfizer says trials on lymphoma drug ‘positive,’ extends life of patients 

HQ Team March 12, 2024: Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded.

Read More
Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24% of people involved in trials, the company announced.
Drugs Health Pharma

Novo Nordisk says Ozempic reduces kidney disease progression 

HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.

Read More
US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary goals of efficacy and safety in patients, according to a company statement.
Drugs Health Pharma

Akero Therapeutics says mid-stage trials on drug for fatty liver disease positive

HQ Team March 4, 2024: US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary.

Read More
An asthma drug, omalizumab, can “significantly” reduce the risk of allergic reactions caused by multiple foods among children and adults in case of accidental exposure, according to a study funded by the US medical research agency.
Drugs Health Pharma

Omalizumab or Xolair can lower risk of food allergies in kids, adults: NIH

HQ Team February 26, 2024: An asthma drug, omalizumab, can “significantly” reduce the risk of allergic reactions caused by multiple foods among children.

Read More
The USFDA has cleared AstraZeneca’s lung cancer drug Tagrisso with chemotherapy for treatment in adult patients.
Drugs Health Pharma

AstraZeneca’s non-small lung cancer therapy gets FDA clearance

HQ Team February 17, 2024: The USFDA has cleared AstraZeneca’s Tagrisso with chemotherapy for treatment in adult patients with non-small cell lung cancer..

Read More
Gilead Sciences, Inc., announced it has discontinued trials on a drug to treat blood cancer after the US regulatory body placed the experiments on full clinical hold, according to a company statement.
Drugs Health Pharma

Gilead Sciences puts last-stage blood cancer trials on hold after FDA order

HQ Team February 8, 2024: Gilead Sciences, Inc., announced it has discontinued trials on a drug to treat blood cancer after the US.

Read More
Denmark's Novo Nordisk plans to effect a 75% cut in insulin prices in the U.S. market by January 1, 2024.
Drugs Health Medical

Oral insulin successfully tested on animals, human trials set for 2025

Bharti Jayshankar February 5, 2024: Scientists have developed a form of oral insulin, offering an alternative to traditional syringes or insulin pumps. The.

Read More
The first human trials for a vaccine against Nipah virus have been started by the University of Oxford, according to a statement.
Drugs Health Pharma

University of Oxford starts human trials to develop vaccine against Nipah virus 

HQ Team January 11, 2023: The first human trials for a vaccine against Nipah virus have been started by the University of Oxford,.

Read More
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More